Tradestie Institutional Equity Comparison Engine

MRNA vs INSM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MRNA Overall Edge

MRNA Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Momentum & Technical while INSM counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus INSM at N/M Forward P/E and -41.7% operating margin (+268.4% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against INSM sits in CONSOLIDATION (37th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
MRNA 23.0x vs INSM N/M Fwd P/E
Growth & Margin Winner INSM
Op Margin -80.8% vs -41.7% ยท YoY +29.2% vs +268.4%
Momentum & Technical Winner MRNA
1Y +706.5% vs -30.6% ยท 52W Pos 67% vs 42%
Options & Structure Winner INSM
CONSOLIDATION (52nd %ile IV) vs CONSOLIDATION (37th %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
INSM NASDAQ
Insmed, Inc.
Pharmaceutical Preparations
$141.33
-2.17% 1D
Market Cap $31.7B
1M Return +48.67%
1Y Return -30.57%
Forward P/E N/M
Unified AI Score
39.6 / 100 SELL
Tech 15.0 Fund 40.0 Flow 69.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% INSM -30.57% Spread: +737.02 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MRNA Revenue INSM Revenue MRNA Op. Margin INSM Op. Margin Margin Edge
FY2018 $140M $10M -306.0% -3124.9% MRNA
FY2019 $60M $140M -906.8% -172.4% INSM
FY2020 $800M $160M -95.0% -161.3% MRNA
FY2021 $18.5B $190M 72.0% -199.0% MRNA
FY2022 $19.3B $250M 48.9% -186.4% MRNA
FY2023 $6.85B $310M -61.9% -232.5% MRNA
FY2024 $3.24B $360M -121.9% -241.5% MRNA
FY2025 $1.94B $610M -158.1% -205.6% MRNA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (7) vs INSM (3)
Institutional Metric MRNA INSM Criterion Row Winner
Market Capitalization Scale $80.7B $31.7B Larger Scale MRNA
Trailing P/E Ratio Valuation 23.0x 106.4x Lower Multiple MRNA
Forward P/E Ratio Valuation 23.0x N/M Lower Multiple MRNA
Revenue Growth (YoY) Growth +29.2% +268.4% Higher Growth INSM
Operating Margin (TTM) Profitability -80.8% -41.7% Higher Margin INSM
Net Profit Margin Profitability -110.5% -39.9% Higher Margin INSM
Return on Equity (ROE) Capital Efficiency -34.5% -72.5% Higher ROE MRNA
52-Week Range Position Momentum 67% ($22โ€“$281) 42% ($90โ€“$213) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 0.37ฮฒ ยท 91% Vol Lower Realized Risk MRNA
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 39.6 / 100 (SELL) Higher Composite MRNA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs INSM Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
INSM CONSOLIDATION
73d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 37th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live INSM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor INSM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.